Marijuana Research Today is a free monthly online journal that collates and summarizes the latest research about Marijuana, including details on benefits, cancer, effects, uses, addiction.

Volume 7 (2010), Issue 7 (July)

1. JWH018, a common constituent of 'Spice' herbal blends, is a potent and efficacious cannabinoid CB receptor agonist.
   Br J Pharmacol, 160(3): 585-93. [Abstract] [Full-text]
2. Gender differences in body consciousness and substance use among high-risk adolescents.
   Subst Use Misuse, 45(10): 1623-35. [Abstract] [Full-text]
3. Methamphetamine use among newly diagnosed HIV-positive young men in North Carolina, United States, from 2000 to 2005.
   PLoS One, 5(6): e11314. [Abstract] [Full-text]
4. Endocannabinoid modulation of hyperaemia evoked by physiologically relevant stimuli in the rat primary somatosensory cortex.
   Br J Pharmacol, 160(3): 736-46. [Abstract] [Full-text]
5. Drug- and cue-induced reinstatement of cannabinoid-seeking behaviour in male and female rats: influence of ovarian hormones.
   Br J Pharmacol, 160(3): 724-35. [Abstract] [Full-text]
6. The effects of Delta-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis.
   Br J Pharmacol, 160(3): 712-23. [Abstract] [Full-text]
7. How important are sex differences in cannabinoid action?
   Br J Pharmacol, 160(3): 544-8. [Abstract] [Full-text]
8. Phytocannabinoids beyond the Cannabis plant - do they exist?
   Br J Pharmacol, 160(3): 523-9. [Abstract] [Full-text]
9. Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models.
   Br J Pharmacol, 160(3): 511-22. [Abstract] [Full-text]
10. Animal models of cannabinoid reward.
    Br J Pharmacol, 160(3): 499-510. [Abstract] [Full-text]
11. The endocannabinoid system as a target for the treatment of neurodegenerative disease.
    Br J Pharmacol, 160(3): 480-98. [Abstract] [Full-text]
12. Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery?
    Br J Pharmacol, 160(3): 454-66. [Abstract] [Full-text]
13. Structural MRI findings in long-term cannabis users: what do we know?
    Subst Use Misuse, 45(11): 1787-808. [Abstract] [Full-text]
14. Implicit and explicit affective associations towards cannabis use in patients with recent-onset schizophrenia and healthy controls.
    Psychol Med, 40(8): 1325-36. [Abstract] [Full-text]
15. Opposite relationships between cannabis use and neurocognitive functioning in bipolar disorder and schizophrenia.
    Psychol Med, 40(8): 1337-47. [Abstract] [Full-text]
16. Effect of hydrolysis on identifying prenatal cannabis exposure.
    Anal Bioanal Chem, 397(6): 2335-47. [Abstract] [Full-text]
17. Risky health behaviors among mothers-to-be: the impact of adverse childhood experiences.
    Acad Pediatr, 10(4): 245-51. [Abstract] [Full-text]
18. Illicit drug consumption estimations derived from wastewater analysis: A critical review.
    Sci Total Environ. [Abstract] [Full-text]
19. The Use of Tobacco and Cannabis at an International Music Festival.
    Eur Addict Res, 16(4): 208-212. [Abstract] [Full-text]
20. Local politics and retail cannabis markets: the case of the Dutch coffeeshops.
    Int J Drug Policy, 21(4): 315-20. [Abstract] [Full-text]
21. The case for small-scale domestic cannabis cultivation.
    Int J Drug Policy, 21(4): 271-5. [Abstract] [Full-text]
22. Substance use disorder comorbidity with schizophrenia in families of Mexican and Central American ancestry.
    Schizophr Res, 120(1): 87-94. [Abstract] [Full-text]
23. Cannabinoid administration increases 5HT1A receptor binding and mRNA expression in the hippocampus of adult but not adolescent rats.
    Neuroscience, 169(1): 315-24. [Abstract] [Full-text]
24. Detection of JWH-018 metabolites in smoking mixture post-administration urine.
    Forensic Sci Int, 200(1): 141-7. [Abstract] [Full-text]
25. Cannabis use disorders in schizophrenia: effects on cognition and symptoms.
    Schizophr Res, 120(1): 95-100. [Abstract] [Full-text]
26. Mental health problems and interest in marijuana treatment among marijuana-using college students.
    Addict Behav, 35(9): 826-33. [Abstract] [Full-text]
27. Gender moderates the impact of stereotype threat on cognitive function in cannabis users.
    Addict Behav, 35(9): 834-9. [Abstract] [Full-text]
28. Are cannabis use disorders associated with an earlier age at onset of psychosis? A study in first episode schizophrenia.
    Schizophr Res, 120(1): 101-7. [Abstract] [Full-text]
29. The differentiation of fibre- and drug type Cannabis seedlings by gas chromatography/mass spectrometry and chemometric tools.
    Forensic Sci Int, 200(1): 87-92. [Abstract] [Full-text]
30. Procedural and Declarative Memory Task Performance, and the Memory Consolidation Function of Sleep, in Recent and Abstinent Ecstasy/Mdma Users.
    J Psychopharmacol. [Abstract] [Full-text]
31. Primary care services provided to adolescents in detention: a cross-sectional study using ICPC-2.
    Acta Paediatr, 99(7): 1060-4. [Abstract] [Full-text]
32. Illicit drugs in wastewater of the city of Zagreb (Croatia) - Estimation of drug abuse in a transition country.
    Environ Pollut, 158(8): 2686-93. [Abstract] [Full-text]
33. Early cannabis use and estimated risk of later onset of depression spells: Epidemiologic evidence from the population-based World Health Organization World Mental Health Survey Initiative.
    Am J Epidemiol, 172(2): 149-59. [Abstract] [Full-text]
34. The mediation role of licit drugs in the influence of socializing on cannabis use among adolescents: A quantitative approach.
    Addict Behav, 35(10): 890-5. [Abstract] [Full-text]
35. The frontal assessment battery (FAB) reveals neurocognitive dysfunction in substance-dependent individuals in distinct executive domains: Abstract reasoning, motor programming, and cognitive flexibility.
    Addict Behav, 35(10): 875-81. [Abstract] [Full-text]
36. School disrepair and substance use among regular and alternative high school students.
    J Sch Health, 80(8): 387-93. [Abstract] [Full-text]
37. Cannabidiol injected into the bed nucleus of the stria terminalis modulates baroreflex activity through 5-HT1A receptors.
    Pharmacol Res, 62(3): 228-36. [Abstract] [Full-text]
38. Intra-dorsal periaqueductal gray administration of cannabidiol blocks panic-like response by activating 5-HT1A receptors.
    Behav Brain Res, 213(2): 225-9. [Abstract] [Full-text]
39. Intra-dorsal periaqueductal gray administration of cannabidiol blocks panic-like response by activating 5-HT1A receptors.
    Behav Brain Res, 213(2): 225-9. [Abstract] [Full-text]
40. A follow-up study: acute behavioural effects of Delta(9)-THC in female heterozygous Neuregulin 1 transmembrane domain mutant mice.
    Psychopharmacology (Berl), 211(3): 277-89. [Abstract] [Full-text]
41. Effects of alcohol on trajectories of physical aggression among urban youth: an application of latent trajectory modeling.
    J Youth Adolesc, 39(9): 1012-26. [Abstract] [Full-text]
42. Altered architecture and functional consequences of the mesolimbic dopamine system in cannabis dependence.
    Addict Biol, 15(3): 266-76. [Abstract] [Full-text]
43. Substance use risk profiles and associations with early substance use in adolescence.
    J Behav Med. [Abstract] [Full-text]
44. The feasibility of converting Cannabis sativa L. oil into biodiesel.
    Bioresour Technol, 101(21): 8457-60. [Abstract] [Full-text]
45. The feasibility of converting Cannabis sativa L. oil into biodiesel.
    Bioresour Technol, 101(21): 8457-60. [Abstract] [Full-text]
46. Patterns and correlates of drug-related ED visits: results from a national survey.
    Am J Emerg Med. [Abstract] [Full-text]
47. Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression.
    Immunobiology, 215(8): 598-605. [Abstract] [Full-text]
48. Can adolescents learn self-control? Delay of gratification in the development of control over risk taking.
    Prev Sci, 11(3): 319-30. [Abstract] [Full-text]
49. Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis.
    Neuropsychopharmacology, 35(9): 1879-85. [Abstract] [Full-text]
50. Cannabis-based medicines in multiple sclerosis--a review of clinical studies.
    Immunobiology, 215(8): 658-72. [Abstract] [Full-text]
51. Examining Attachment to God and Health Risk-Taking Behaviors in College Students.
    J Relig Health. [Abstract] [Full-text]
52. A structural insight into the molecular recognition of a (-)-Delta9-tetrahydrocannabinol and the development of a sensitive, one-step, homogeneous immunocomplex-based assay for its detection.
    J Mol Biol, 400(4): 803-14. [Abstract] [Full-text]
53. Recent substance intake among patients admitted to acute psychiatric wards: physician's assessment and on-site urine testing compared with comprehensive laboratory analyses.
    J Clin Psychopharmacol, 30(4): 455-9. [Abstract] [Full-text]
54. Antipsychotic agents for the treatment of substance use disorders in patients with and without comorbid psychosis.
    J Clin Psychopharmacol, 30(4): 417-24. [Abstract] [Full-text]
55. Prenatal cocaine exposure related to cortisol stress reactivity in 11-year-old children.
    J Pediatr, 157(2): 288-295.e1. [Abstract] [Full-text]
56. Patterns of drug use and abuse among aging adults with and without HIV: a latent class analysis of a US Veteran cohort.
    Drug Alcohol Depend, 110(3): 208-20. [Abstract] [Full-text]
57. Modeling the impact of age and sex on a dimension of poly-substance use in adolescence: a longitudinal study from 11- to 17-years-old.
    Drug Alcohol Depend, 110(3): 193-9. [Abstract] [Full-text]
58. Cannabis use and educational achievement: findings from three Australasian cohort studies.
    Drug Alcohol Depend, 110(3): 247-53. [Abstract] [Full-text]
59. Establishment of recombinant cannabinoid receptor assays and characterization of several natural and synthetic ligands.
    Naunyn Schmiedebergs Arch Pharmacol, 382(2): 177-91. [Abstract] [Full-text]
60. A comparison of psychosocial and cognitive functioning between depressed and non-depressed patients with cannabis dependence.
    J Addict Dis, 29(3): 325-37. [Abstract] [Full-text]
61. Cannabis induced acute coronary syndrome in a young female.
    Int J Cardiol, 143(1): e4-6. [Abstract] [Full-text]
62. Adolescent initiation of licit and illicit substance use: Impact of intrauterine exposures and post-natal exposure to violence.
    Neurotoxicol Teratol. [Abstract] [Full-text]
63. DSM-based problem gambling: Increasing the odds of heavy drinking in a national sample of U.S. college athletes?
    J Psychiatr Res. [Abstract] [Full-text]
64. Leisure time activities that predict initiation, progression and reduction of cannabis use: a prospective, population-based panel survey.
    Drug Alcohol Rev, 29(4): 378-84. [Abstract] [Full-text]
65. Models of policy-making and their relevance for drug research.
    Drug Alcohol Rev, 29(4): 352-7. [Abstract] [Full-text]
66. Cannabis use in patients with a first psychotic episode and subjects at ultra high risk of psychosis: impact on psychotic- and pre-psychotic symptoms.
    Aust N Z J Psychiatry, 44(8): 721-8. [Abstract] [Full-text]
67. Drug classification: science, politics, both or neither?
    Addiction, 105(7): 1146-9. [Abstract] [Full-text]
68. What are the policy lessons of National Alcohol Prohibition in the United States, 1920-1933?
    Addiction, 105(7): 1164-73. [Abstract] [Full-text]
69. Continuous, categorical and mixture models of DSM-IV alcohol and cannabis use disorders in the Australian community.
    Addiction, 105(7): 1246-53. [Abstract] [Full-text]
70. Sexual orientation and substance use trajectories in emerging adulthood.
    Addiction, 105(7): 1235-45. [Abstract] [Full-text]
71. Spice drugs as a new trend: mode of action, identification and legislation.
    Toxicol Lett, 197(3): 157-62. [Abstract] [Full-text]
72. Neurophysiological and cognitive effects of smoked marijuana in frequent users.
    Pharmacol Biochem Behav, 96(3): 333-41. [Abstract] [Full-text]
73. Prevalence of psychotic symptoms and their risk factors in urban Tanzania.
    Int J Environ Res Public Health, 7(6): 2514-25. [Abstract] [Full-text]
74. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.
    Int J Neuropsychopharmacol, 13(7): 861-76. [Abstract] [Full-text]
75. Risk factors predicting onset and persistence of subthreshold expression of bipolar psychopathology among youth from the community.
    Acta Psychiatr Scand, 122(3): 255-66. [Abstract] [Full-text]
76. Performance evaluation of the DrugWipe((R)) 5/5 (+) on-site oral fluid screening device.
    Int J Legal Med. [Abstract] [Full-text]
77. Screen time and risk behaviors in 10- to 16-year-old Canadian youth.
    Prev Med. [Abstract] [Full-text]
78. How ideology shapes the evidence and the policy: what do we know about cannabis use and what should we do?
    Addiction, 105(8): 1326-30. [Abstract] [Full-text]
79. The impact of early-onset cannabis use on functional brain correlates of working memory.
    Prog Neuropsychopharmacol Biol Psychiatry, 34(6): 837-45. [Abstract] [Full-text]
80. Interactions between specific parameters of cannabis use and verbal memory.
    Prog Neuropsychopharmacol Biol Psychiatry, 34(6): 871-6. [Abstract] [Full-text]
81. Substance use and common child mental health problems: examining longitudinal associations in a British sample.
    Addiction, 105(8): 1484-96. [Abstract] [Full-text]
82. Computer-delivered interventions for alcohol and tobacco use: a meta-analysis.
    Addiction, 105(8): 1381-90. [Abstract] [Full-text]
83. Functional MRI evidence for inefficient attentional control in adolescent chronic cannabis abuse.
    Behav Brain Res. [Abstract] [Full-text]
84. Does dopamine mediate the psychosis-inducing effects of cannabis? A review and integration of findings across disciplines.
    Schizophr Res, 121(1): 107-17. [Abstract] [Full-text]
85. Substance abuse and mental health disparities: comparisons across sexual identity groups in a national sample of young Australian women.
    Soc Sci Med, 71(4): 824-31. [Abstract] [Full-text]
86. Whither RDS? An investigation of Respondent Driven Sampling as a method of recruiting mainstream marijuana users.
    Harm Reduct J, 7: 15. [Abstract] [Full-text]
87. Self-control and its relation to joint developmental trajectories of cannabis use and depressive mood symptoms.
    Drug Alcohol Depend. [Abstract] [Full-text]
88. Evaluation of drugs of abuse use and trends in a prison through wastewater analysis.
    Environ Int. [Abstract] [Full-text]
89. A retrospective analysis of cannabis use in a cohort of mentally ill patients in Sri Lanka and its implications on policy development.
    Subst Abuse Treat Prev Policy, 5: 16. [Abstract] [Full-text]
90. Brief integrative multiple behavior intervention effects and mediators for adolescents.
    J Behav Med. [Abstract] [Full-text]
91. The Impact of Cannabis Use on Cognitive Functioning in Patients With Schizophrenia: A Meta-analysis of Existing Findings and New Data in a First-Episode Sample.
    Schizophr Bull. [Abstract] [Full-text]
92. Acute mutism: a useful lesson.
    Emerg Med J. [Abstract] [Full-text]
93. The family as mediator of the impact of parent-youth acculturation/enculturation and inner-city stressors on Mexican American youth substance use.
    Cultur Divers Ethnic Minor Psychol, 16(3): 404-12. [Abstract] [Full-text]
94. Disposition of cannabinoids in oral fluid after controlled around-the-clock oral THC administration.
    Clin Chem, 56(8): 1261-9. [Abstract] [Full-text]
95. Cannabinoids excite circadian clock neurons.
    J Neurosci, 30(30): 10061-6. [Abstract] [Full-text]
96. Requirement of cannabinoid CB(1) receptors in cortical pyramidal neurons for appropriate development of corticothalamic and thalamocortical projections.
    Eur J Neurosci. [Abstract] [Full-text]

© 2004-2011 Marijuana Research Today. All Rights Reserved.